ARTICLE | Clinical News
LG631-CD34 regulatory update
February 25, 2013 8:00 AM UTC
Lentigen said FDA granted Orphan Drug designation for LG631-CD34 for bone marrow protection in the treatment of glioblastoma multiforme (GBM). The stem cell therapy product expressing a variant of met...